Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Boston Scientific said today that it won CE Mark approval in the European Union for its Ranger drug-eluting balloon for treating peripheral artery disease.
Marlborough, Mass.-based Boston Scientific said the paclitaxel-coated Ranger balloon is designed to be used during percutaneous transluminal angioplasty to deliver the anti-stenotic drug without leaving behind a permanent implant. The Ranger device is in “full European market launch,” according to a press release. Read more
Intersect ENT said today that it hopes to raise as much as $65 million in an initial public offering of 5 million shares.
Intersect, which makes drug-eluting devices designed to treat ear, nose & throat conditions, said it plans to price the shares at $11 to $13 apiece, meaning the offering could raise between $55 million and $65 million. Read more
Minnesota-based medtech giant St. Jude Medical is broaching new ground in the spinal pain market with the $200 million acquisition of NeuroTherm, maker of radiofrequency ablation therapies.
The acquisition bolsters St. Jude’s chronic pain portfolio with a device that comes into play earlier in the ‘chronic pain continuum,’ the company said. The deal would also make St. Jude the only company to offer both radiofrequency ablation and spinal cord stimulation devices. Read more